The trajectory of Sildenafil presents a complex case for stakeholders in the drug sector. While initially a tremendous success, producing huge profits, the exclusivity expiration and the subsequent flood of generic versions have drastically affected income. This presents questions about the future profitability of analogous therapeutic developme… Read More